Non-small-cell lung cancer

Lizza Hendriks(Maastricht University), Martin Reck(German Center for Lung Research)

Nature Reviews Disease Primers

September 26, 2024

10.1038/s41572-024-00551-9

Cited by 407

Related Papers

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|2.3k

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

|The Lancet|2008|1.2k

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

|The Lancet Oncology|2014|948

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

|The Lancet Respiratory Medicine|2019|937

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

|Annals of Oncology|2023|782